Estimating the association between antibiotic exposure and colonization with extended-spectrum β-lactamase-producing Gram-negative bacteria using machine learning methods: a multicentre, prospective cohort study

Clinical Microbiology and Infection

Volumn 26, Issue 1, 2020, Pages 87-94

  Tacconelli, E ^a,b   Gorska A ^c   De Angelis, G ^d   Lammens, C ^e   Restuccia, G ^f   Schrenzel, J ^g   Huson, D H ^c   Carevic B ^h   Preotescu L ⁱ   Carmeli, Y ^j,k   Kazma, M ^j,k   Spanu, T ^d   Carrara, E ^b   Malhotra Kumar, S ^e   Gladstone, B P ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f UNIVERSITY OF CATANIA   (Italy)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h CLINICAL CENTER OF SERBIA   (Serbia)

ⁱ CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^j TEL AVIV UNIVERSITY   (Israel)

^k MINISTRY OF HEALTH   (Israel)

more..

Author keywords

Antibiotics usage; Colonization; Extended spectrum lactamase; Incidence rate; Machine learning

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; MACROLIDE; QUINOLONE DERIVATIVE; TETRACYCLINE; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ADULT; AGE; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; COHORT ANALYSIS; FEMALE; GRAM NEGATIVE BACTERIUM; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOM FOREST; SPRING; WINTER; ADOLESCENT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECT; ENZYMOLOGY; GRAM NEGATIVE INFECTION; INCIDENCE; ITALY; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; ROMANIA; SERBIA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG THERAPY, COMBINATION; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALIZATION; HUMANS; INCIDENCE; ITALY; MACHINE LEARNING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; ROMANIA; SERBIA; YOUNG ADULT;

EID: 85068874561     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2019.05.013     Document Type: Article

References (36)

1. Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D.L., et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18 (2018), 318–327.
2. Tacconelli, E., De Angelis, G., Cataldo, M.A., Pozzi, E., Cauda, R., Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 61 (2008), 26–38.
3. Kang, C.-I., Kim, S.-H., Kim, D.M., Park, W., Lee, K., Kim, H., et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Infect Contr Hosp Epidemiol 25 (2004), 860–867.
4. Harris, A.D., Samore, M.H., Lipsitch, M., Kaye, K.S., Perencevich, E., Carmeli, Y., Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis 34 (2002), 1558–1563.
5. Hyle, E.P., Bilker, W.B., Gasink, L.B., Lautenbach, E., Impact of different methods for describing the extent of prior antibiotic exposure on the association between antibiotic use and antibiotic-resistant infection. Infect Contr Hosp Epidemiol 28 (2007), 647–654.
6. Schechner, V., Temkin, E., Harbarth, S., Carmeli, Y., Schwaber, M.J., Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance. Clin Microbiol Rev 26 (2013), 289–307.
7. Yu, W., Liu, T.B., Valdez, R., Gwinn, M., Khoury, M.J., Application of support vector machine modeling for prediction of common diseases: the case of diabetes and pre-diabetes. BMC Med Inform Decis Mak, 10, 2010.
8. Guyon, I.W.J.B.S., Vapnik, V., Gene selection for cancer classification using support vector machines. Mach Learn 46 (2002), 389–422.
9. Mittag, F., Büchel, F., Saad, M., Jahn, A., Schulte, C., Bochdanovits, Z., et al. Use of support vector machines for disease risk prediction in genome-wide association studies: concerns and opportunities. Hum Mutat 33 (2012), 1708–1718.
10. Oh, J., Makar, M., Fusco, C., McCaffrey, R., McCaffrey, R., Rao, K., Ryan, E.E., et al. A generalizable, data-driven approach to predict daily risk of Clostridium difficile infection at two large academic health centers. Infect Contr Hosp Epidemiol 39 (2018), 425–433.
11. DeLisle, S., Kim, B., Deepak, J., Siddiqui, T., Gundlapalli, A., Samore, M., et al. Using the electronic medical record to identify community-acquired pneumonia: toward a replicable automated strategy. PLoS One, 13, 2013, 8.
12. Chae, S., Kwon, S., Lee, D., Predicting infectious disease using deep learning and big data. Int J Environ Res Pub Health, 15, 2018, 1596.
13. Moradigaravand, D., Palm, M., Farewell, A., Mustonen, V., Warringer, J., Parts, L., Prediction of antibiotic resistance in Escherichia coli from large-scale pan-genome data. PLoS Comput Biol, 14, 2018, e1006258.
14. Crofts, T.A., Gasparrini, A.J., Dantas, G., Next-generation approaches to understand and combat the antibiotic resistome. Nat Rev Microbiol 15 (2017), 422–434.
15. De Angelis, G., Restuccia, G., Venturiello, S., Cauda, R., Malhotra-Kumar, S., Goossens, H., et al. Nosocomial acquisition of methicillin-resistant Staphyloccocus aureus (MRSA) and extended-spectrum β-lactamase (ESBL) Enterobacteriaceae in hospitalised patients: a prospective multicenter study. BMC Infect Dis, 12, 2012, 74.
16. Meletiadis, J., Turlej-Rogacka, A., Lerner, A., Adler, A., Tacconelli, E., Mouton, J.W., the SATURN Diagnostic Study Group. Amplification of antimicrobial resistance in gut flora of patients treated with ceftriaxone. Antimicrob Agents Chemother, 24, 2017, 61.
17. De Backer, S., Xavier, B.B., Vanjari, L., Coppens, J., Lammens, C., Vemu, L., et al. Remarkable geographical variations between India and Europe in carriage of the staphylococcal surface protein-encoding sasX/sesI and in the population structure of methicillin-resistant Staphylococcus aureus belonging to clonal complex 8. Clin Microbiol Infect, 25, 2019, 628 e1–e7.
18. Royston, P., Parmar, M.K.B., Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 21 (2002), 2175–2197.
19. MongoDB. 2017. Available at: www.mongodb.com: https://www.mongodb.com.
20. Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., et al. Scikit-learn: machine learning in Python. J Mach Learn Res 12 (2011), 2825–2830.
21. Carmeli, Y., Samore, M.H., Huskins, C., The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. Arch Intern Med 159 (1999), 2461–2468.
22. Han, J.H., Bilker, W.B., Nachamkin, I., Tolomeo, P., Mao, X., Fishman, N.O., et al. Impact of antibiotic use during hospitalization on the development of gastrointestinal colonization with Escherichia coli with reduced fluoroquinolone susceptibility. Infect Contr Hosp Epidemiol 34 (2014), 1070–1076.
23. Monnet, D.L., MacKenzie, F.M., López-Lozano, J.M., Beyaer, A., Camacho, M., Wilson, R., et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996–2000. Emerg Infect Dis 10 (2004), 1432–1441.
24. Tacconelli, E., De Angelis, G., Cataldo, M.A., Mantengoli, E., Spanu, T., Pan, A., et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother 53 (2009), 4264–4269.
25. Greenhalgh, K., Meyer, K.M., Aagaard, K.M., Wilmes, P., The human gut microbiome in health: establishment and resilience of microbiota over a lifetime. Environ Microbiol 18 (2016), 2103–2116.
26. Willmann, M., El-Hadidi, M., Huson, D.H., Schütz, M., Weidenmaier, C., Autenrieth, I.B., et al. Antibiotic selection pressure determination through sequence-based metagenomics. Antimicrob Agents Chemother 59 (2015), 7335–7345.
27. Mitchison, D., Davies, G., The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis 16 (2012), 724–732.
28. Fischbach, M.A., Combination therapies for combating antimicrobial resistance. Curr Opin Microbiol 14 (2011), 519–523.
29. Lengauer, T., Pfeifer, N., Kaiser, R., Personalized HIV therapy to control drug resistance. Drug Discov Today Technol 11 (2014), 57–64.
30. Le Minh V, Thi Khanh Nhu, N., Vinh Phat, V., Thompson, C., Huong Lan, N.P., Thieu Nga, T.V., et al. In vitro activity of colistin in antimicrobial combination against carbapenem-resistant Acinetobacter baumannii isolated from patients with ventilator-associated pneumonia in Vietnam. J Med Microbiol 64 (2015), 1162–1169.
31. Tamma, P.D., Cosgrove, S.E., Maragakis, L.L., Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev 25 (2012), 450–470.
32. Yim, J., Smith, J.R., Rybak, M.J., Role of Combination antimicrobial therapy for vancomycin-resistant Enterococcus faecium infections: review of the current evidence. Pharmacotherapy 37 (2017), 579–592.
33. Papst, L., Beovic, B., Pulcini, C., Durante-Mangoni, E., Rodríguez-Baño, J., Kaye, K., et al. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clin Microbiol Infect 24 (2018), 1070–1076.
34. Paul, M., Carmeli, Y., Durante-Mangoni, E., Mouton, J.W., Tacconelli, E., Theuretzbacher, U., et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69 (2014), 2305–2309.
35. Gazin, M., Paasch, F., Goossens, H., Malhotra-Kumar, S., Mosar, W.P., Teams, S.W.S., Current trends in culture-based and molecular detection of extended-spectrum-β-lactamase-harboring and carbapenem-resistant Enterobacteriaceae. J Clin Microbiol 50 (2012), 1140–1146.
36. Uppsala Monitoring Centre—WHO Collaborating Centre for International Drug Monitoring. Guidelines for setting up and running a pharmacovigilance centre—safety monitoring of medicinal products. 2000, UMC, London.